Ruxton focuses on glutamate transporters, the critical protein that keeps the neurotransmitter glutamate at normal levels. We have built a comprehensive suite of biological assays to study the effect of drug candidates on glutamate transporter promoter, protein and function. We are discovering drugs for a wide range of neurological disorders that result from abnormal levels of synaptic glutamate.

Our approach to such an important medical area has led us to be joined by some of the world's most respected venture capital firms.